WO2004037997A3 - Fragments and activity of rel protein in m. tuberculosis adn other uses thereof - Google Patents

Fragments and activity of rel protein in m. tuberculosis adn other uses thereof Download PDF

Info

Publication number
WO2004037997A3
WO2004037997A3 PCT/US2003/033692 US0333692W WO2004037997A3 WO 2004037997 A3 WO2004037997 A3 WO 2004037997A3 US 0333692 W US0333692 W US 0333692W WO 2004037997 A3 WO2004037997 A3 WO 2004037997A3
Authority
WO
WIPO (PCT)
Prior art keywords
tuberculosis
present
adn
fragments
activity
Prior art date
Application number
PCT/US2003/033692
Other languages
French (fr)
Other versions
WO2004037997A2 (en
Inventor
David Howard Avarbock
Harvey Rubin
Andrew Brian Avarbock
Original Assignee
Univ Pennsylvania
David Howard Avarbock
Harvey Rubin
Andrew Brian Avarbock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, David Howard Avarbock, Harvey Rubin, Andrew Brian Avarbock filed Critical Univ Pennsylvania
Priority to AU2003294235A priority Critical patent/AU2003294235A1/en
Publication of WO2004037997A2 publication Critical patent/WO2004037997A2/en
Publication of WO2004037997A3 publication Critical patent/WO2004037997A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to mycobacteria. The present invention further relates to M. tuberculosis. The present invention further relates to the RelMtb. The present invention also relates to identifying new antibacterial targets and agents to inhibit mycobacterial growth. The present invention also relates to polynucleotides of RelMtb, Polypeptides of RelMtb, and antibodies that bind RelMtb and methods of using the same.
PCT/US2003/033692 2002-10-22 2003-10-22 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof WO2004037997A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003294235A AU2003294235A1 (en) 2002-10-22 2003-10-22 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42013102P 2002-10-22 2002-10-22
US60/420,129 2002-10-22

Publications (2)

Publication Number Publication Date
WO2004037997A2 WO2004037997A2 (en) 2004-05-06
WO2004037997A3 true WO2004037997A3 (en) 2004-11-18

Family

ID=32176517

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/033692 WO2004037997A2 (en) 2002-10-22 2003-10-22 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
PCT/US2003/033524 WO2004037192A2 (en) 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033524 WO2004037192A2 (en) 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases

Country Status (2)

Country Link
AU (2) AU2003294235A1 (en)
WO (2) WO2004037997A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246349A1 (en) * 2009-04-20 2010-11-03 BKG Pharma ApS Treatment of infectious diseases
US8952034B2 (en) 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
AU2011272787B2 (en) 2010-07-02 2015-06-18 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
NZ716420A (en) 2011-05-10 2017-05-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (en) 2011-07-01 2018-04-28
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN103232447B (en) * 2013-04-02 2015-06-03 陕西科技大学 3-acetyl-5-acetylimino-2-(N-phenothiazinyl)-1,3,4-thiadiazole, and preparation method and application thereof
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109385439A (en) * 2018-09-18 2019-02-26 上海晶诺生物科技有限公司 The one recombination TM4 phage library and its application for constructing nadh dehydrogenase gene family missing mycobacterium tuberculosis
WO2023201199A2 (en) * 2022-04-11 2023-10-19 The Johns Hopkins University Tuberculosis vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834279A (en) * 1996-03-07 1998-11-10 Trustees Of The University Of Pennsylvania Methods of identifying compounds that inhibit DNA synthesis in mycobacterium tuberculosis and compositions, reagents and kits for performing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834279A (en) * 1996-03-07 1998-11-10 Trustees Of The University Of Pennsylvania Methods of identifying compounds that inhibit DNA synthesis in mycobacterium tuberculosis and compositions, reagents and kits for performing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AVARBOCK D. ET AL: "Differential Regulation of Opposing RelMtb Activities by the Aminoacylation State of a tRNA·Ribosome·mRNA·RelMtb Complex", BIOCHEMISTRY, vol. 39, no. 38, September 2000 (2000-09-01), pages 11640 - 11648, XP002981909 *
PRIMM T.P. ET AL: "The Stringent Response of Mycobacterium tuberculosis Is Required for Long-Term Survival", J. OF BACTERIOLOGY, vol. 182, no. 17, September 2000 (2000-09-01), pages 4889 - 4898, XP002981910 *

Also Published As

Publication number Publication date
WO2004037192A2 (en) 2004-05-06
AU2003285946A8 (en) 2004-05-13
AU2003294235A1 (en) 2004-05-13
WO2004037192A3 (en) 2006-09-14
WO2004037997A2 (en) 2004-05-06
AU2003294235A8 (en) 2004-05-13
AU2003285946A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
EP1789447A4 (en) Method of delivering rna interference and uses thereof
EP2289944A3 (en) Bispecific antibody substituting for functional proteins
EP2322552A3 (en) IL-1beta binding antibodies and fragments thereof
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
EP2298805A3 (en) Optimized Fc variants and methods for their generation
ATE412432T1 (en) INTERNALIZING ERBB2 ANTIBODIES
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2000005249A3 (en) Synthetic peptides and methods of use for autoimmune disease therapies
SG145725A1 (en) Anti-vegf antibodies
WO2004081190A3 (en) Uses of il-23 agonists and antagonists; related reagents
WO2005007653A3 (en) Substituted tetrahydro-1h-pyrazolo[3,4-c]pyridines, compositions containing same and use
WO2004037997A3 (en) Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
ATE419267T1 (en) SPACIALLY DEFINED MACROCYCLES CONTAINING PEPTIDE BINDING SURROGATES
WO2006056487A3 (en) Peptides useful as dual caspase-2/-6 inhibitors and their biological applications
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2003046009A1 (en) ANTI-IL13 RECEPTOR α1 NEUTRALIZING ANTIBODY
WO2004013290A3 (en) Compositions and methods for molecular biology
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2004094476A3 (en) Compositions and methods relating to stop-1
AU2003304180A1 (en) Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
WO2005000876A3 (en) Ring finger family proteins and uses related thereto
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
WO2003087051A3 (en) Methods for identifying allosteric sites
WO2004035804A3 (en) Crystals and stuctures of a bacterial nucleic acid binding protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP